CDK4 and neoplasm: Similarly, inhibitors of the Cyclin-dependent Kinases (CDKs), such as the CDK4/6 inhibitor Palbociclib, are being used to target tumours with uncontrolled cell cycle progression [29, 30], for instance, following the loss of the CDK inhibitor p16INK4a [31].